- |||||||||| Clinical, Review, Journal: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. (Pubmed Central) - Oct 10, 2020
There is probably little or no difference between 5-ASA and placebo, and 5-ASA and SASP in commonly reported AEs such as flatulence, abdominal pain, nausea, diarrhea, headache, and dyspepsia. Oral 5-ASA administered once daily has a similar benefit and harm profile as conventional dosing for maintenance of remission in quiescent UC.
- |||||||||| Humira SC (adalimumab/hyaluronidase) / AbbVie, Halozyme, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] OVERLAPPING CROHN'S DISEASE AND SEXUALLY TRANSMITTED DISEASES (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5596; Sexually transmitted diseases should be considered in patients with intestinal symptoms and a history of unprotected intercourses. A comprehensive investigation is important before starting any immunosuppressive treatment.
- |||||||||| Humira SC (adalimumab/hyaluronidase) / AbbVie, Halozyme, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] OVERLAPPING CROHN'S DISEASE AND SEXUALLY TRANSMITTED DISEASES (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3620; Sexually transmitted diseases should be considered in patients with intestinal symptoms and a history of unprotected intercourses. A comprehensive investigation is important before starting any immunosuppressive treatment.
- |||||||||| Humira SC (adalimumab/hyaluronidase) / AbbVie, Halozyme, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] OVERLAPPING CROHN'S DISEASE AND SEXUALLY TRANSMITTED DISEASES (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1636; Sexually transmitted diseases should be considered in patients with intestinal symptoms and a history of unprotected intercourses. A comprehensive investigation is important before starting any immunosuppressive treatment.
- |||||||||| Pentasa oral (mesalazine oral) / Ferring, Takeda
Clinical, Journal: The culprit of mesalamine intolerance: case series and literature review. (Pubmed Central) - Feb 7, 2020 5-aminosalicylic acid and excipients should be taken into consideration together when mesalamine-related adverse events occur. Of note, a diagnosis of excipient intolerance should be paid more attention in the patients with the presentation of acute skin symptoms.
- |||||||||| Differences in persistence of oral mesalazine preparations as monotherapy in patients with ulcerative colitis (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_1670;
The number of prescribed DDD the first year after diagnosis was slightly higher in MEZ users (MEZ 1.75, ASA 1.36, PEN 1.42, SAL 1.40).Conclusion There were significant differences in drug persistence between oral preparations that were not explained by differences in prescription at regional level, but could partially be related to differences in disease severity. These differences could have clinical implications and bear further investigations.
|